#United States #Boston #Clinical Trials #PhaseV #AI/ML Development

PhaseV's Upcoming Webinar on Patient-Centric Clinical Development

PhaseV, well-known for its innovations in AI/ML-driven clinical development, is set to host the second episode of its acclaimed webinar series, titled "Putting Patients First: Novelty, Adaptivity, and Collaboration in Clinical Development.” This important session will take place on May 1, 2025, at 100 PM EST and promises to delve into the essential role of patient-centricity in enhancing clinical trial design.

The focus of this episode is to explore how placing patients at the core of clinical trials can lead to improved efficiency and effectiveness in study processes. A panel of industry leaders will engage in discussions that cover innovative approaches to clinical development that prioritize patient needs, thereby addressing the increasing call for inclusivity and collaboration in the healthcare landscape.

Panel Overview

The upcoming panel includes notable figures:

• - Angela Dobes, Senior Vice President at IBD Plexus, Crohn's & Colitis Foundation
• - Oren Hershkovitz, PhD, CEO of Enlivex Therapeutics
• - Aaron Galluzzi, Consulting Statistician at Alimentiv

The discussion will be moderated by Keren Peri-Hanania, MD, the Medical Director at PhaseV. Participants can expect insightful conversations around the following themes:

• - The impact of patient-centric designs on the efficacy of clinical trials
• - How the integration of real-world data along with causal and adaptive methods can enhance patient stratification, leading to better trial outcomes
• - The significant role of patient advocacy organizations in bridging the gap between sponsors, patients, and technology developers for enhanced research outcomes
• - Real-world examples of collaboration among various stakeholders, including biotech sponsors, CROs, foundations, and tech providers to accelerate drug development while adhering to patient priorities.

Insights from PhaseV Leadership

Raviv Pryluk, PhD, the CEO and Co-founder of PhaseV, emphasizes the importance of this webinar series, stating, "Our sessions are designed not just as discussions but as platforms for sharing practical insights that can effect real change in clinical development." He invites participants to glean actionable strategies for incorporating the latest AI-driven approaches, real-time data analysis, and patient-centered design into their trials, ultimately fostering a more efficient clinical development process.

About PhaseV

PhaseV is at the forefront of advancing clinical development through innovative AI/ML solutions. The platform is already enabling biopharma sponsors and CROs to effectively design and implement adaptive, Bayesian, and fixed clinical trials. By leveraging advanced analytical capabilities, PhaseV supports organizations in uncovering heterogeneous treatment effects and optimizing patient stratification to inform future research and development decisions. Notably, the platform has achieved a remarkable 25% reduction in trial costs, decreased enrollment sizes and durations by up to 40%, and improved the probability of trial success by over 30%. To date, PhaseV has delivered meaningful outcomes for over 30 leading pharma and biotech organizations across a diverse range of therapeutic areas, including oncology, neurology, immunology, and rare diseases.

For more information and to register for the upcoming webinar, please visit www.PhaseVTrials.com and follow PhaseV on LinkedIn.